➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
McKesson
Dow
Express Scripts
Johnson and Johnson

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR M.V.I.-12 LYOPHILIZED

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for M.v.i.-12 Lyophilized

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00024492 Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer Completed INSYS Therapeutics Inc Phase 1 2001-08-01 Liposome entrapped mitoxantrone (LEM) is a mixture of commercially available mitoxantrone HCL (Novantrone) and a combination of lyophilized lipids. Mitoxantrone, the active agent in the investigational formulation, is a currently marketed chemotherapeutic agent. The rationale for development of liposomal formulations is primarily that of improving the safety profile of the drug, which may permit dose intensification and/or an increase in the cumulative dose that may be administered, resulting in enhanced efficacy. LEM will be given to patients with advanced solid tumors to determine the dose of drug these patients can tolerate. Patients will receive intravenous LEM every 21 days until the disease progresses or toxicity occurs requiring treatment discontinuation. Anti-tumor effects of LEM will be assessed and patients will be evaluated for safety and tolerability.
NCT00111956 Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A 2004-04-01 Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00123877 Study of GPX-100 in the Treatment of Metastatic Breast Cancer Terminated Gem Pharmaceuticals Phase 2 2005-03-01 The purpose of this early Phase II multicenter trial is to determine the objective clinical response to GPX-100, an anthracycline similar to doxorubicin, in up to 40 patients with newly diagnosed metastatic breast cancer. GPX-100 is unique among anthracyclines because it is not converted to doxorubicinol during metabolism in the body. This metabolite has been shown to be a major cause of damage to the heart (cardiotoxicity) in laboratory studies. Eligible patients who are enrolled in this study will receive GPX-100 as a single agent at the beginning of as many as 8 three week long cycles of chemotherapy. Objective measurements of tumor response will be made by computed tomography (CT) scans.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for M.v.i.-12 Lyophilized

Condition Name

Condition Name for M.v.i.-12 Lyophilized
Intervention Trials
Healthy 7
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity 2
Stage IVB Squamous Cell Carcinoma of the Oropharynx 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for M.v.i.-12 Lyophilized
Intervention Trials
Ulcer 4
Syndrome 4
Periodontitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for M.v.i.-12 Lyophilized

Trials by Country

Trials by Country for M.v.i.-12 Lyophilized
Location Trials
United States 95
Germany 8
Italy 5
Brazil 4
United Kingdom 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for M.v.i.-12 Lyophilized
Location Trials
Texas 8
Ohio 8
New York 6
California 6
Kansas 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for M.v.i.-12 Lyophilized

Clinical Trial Phase

Clinical Trial Phase for M.v.i.-12 Lyophilized
Clinical Trial Phase Trials
Phase 4 9
Phase 3 7
Phase 2/Phase 3 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for M.v.i.-12 Lyophilized
Clinical Trial Phase Trials
Completed 34
Not yet recruiting 18
Active, not recruiting 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for M.v.i.-12 Lyophilized

Sponsor Name

Sponsor Name for M.v.i.-12 Lyophilized
Sponsor Trials
The University of Texas Health Science Center, Houston 4
Ohio State University Comprehensive Cancer Center 4
GlaxoSmithKline 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for M.v.i.-12 Lyophilized
Sponsor Trials
Other 61
Industry 33
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
McKinsey
Mallinckrodt
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.